Results 11 to 20 of about 24,471 (215)
Vaccines against Meningococcal Diseases
Microorganisms, 2020 Neisseria meningitidis is the main cause of meningitis and sepsis, potentially life-threatening conditions. Thanks to advancements in vaccine development, vaccines are now available for five out of six meningococcal disease-causing serogroups (A, B, C, W,
Mariagrazia Pizza +2 more
doaj +3 more sources
Expert Review of Vaccines, 2002 The successful introduction of a protein-polysaccharide conjugate vaccine against serogroup C meningococci into the UK infant immunization schedule, in combination with a catch-up campaign for individuals less than 18 years of age, has seen virtually all group C disease eliminated in childhood.
Bethell, D, Pollard, A
+7 more sources
Meningococcal Vaccinations [PDF]
Infectious Diseases and Therapy, 2016 Neisseria meningitidis, a gram-negative diplococcal bacterium, is a common asymptomatic nasopharyngeal colonizer that may infrequently lead to invasive disease in the form of meningitis or bacteremia. Six serogroups (A, B, C, W, X and Y) are responsible for the majority of invasive infections.
Crum-Cianflone, Nancy, Sullivan, Eva
openaire +2 more sources
Pediatric Infectious Disease Journal, 2004 The 5 major pathogenic serogroups of the Gram-negative encapsulated bacterium Neisseria meningitidis are A, B, C, Y, and W135. In the 1960s, vaccines consisting of purified capsular polysaccharide antigens were developed against serogroups A, C, Y, and W135.
Rüggeberg, J, Pollard, A
openaire +6 more sources
Meningococcal glycoconjugate vaccines [PDF]
Human Vaccines, 2011 Neisseria meningitidis is a major cause of invasive bacterial infections worldwide. For this reason, efforts to control the disease have been directed at optimizing meningococcal vaccines and implementing appropriate vaccination policies. In the past, plain polysaccharide vaccines containing purified capsular polysaccharides A, C, Y and W135 were ...
GASPARINI, ROBERTO, PANATTO, DONATELLA
openaire +2 more sources
Promising pharmaceutical development of vaccines for the prevention of meningococcal infection
Журнал микробиологии, эпидемиологии и иммунобиологии, 2023 Meningococcal infection (MI) refers to anthroponoses; is an acute infectious disease with an aerosol transmission mechanism, characterized by various forms of the infectious process: from local (nasopharyngitis) and asymptomatic infections to generalized
Maria V. Savkina +3 more
doaj +1 more source
mSphere, 2018 Neisseria meningitidis is a common cause of bacterial meningitis in children and young adults worldwide. The 4CMenB vaccine (Bexsero), developed to combat meningococcal serogroup B (MenB) disease, contains subcapsular antigens that may induce immunity ...
Robert M. Mulhall +12 more
doaj +1 more source
Bacterial outer membrane vesicles and vaccine applications [PDF]
, 2014 Vaccines based on outer membrane vesicles (OMV) were developed more than 20 years ago against Neisseria meningitidis serogroup B. These nano-sized structures exhibit remarkable potential for immunomodulation of immune responses and delivery of “self ...
Acevedo, Reinaldo +10 more
core +2 more sources
Human Vaccines & Immunotherapeutics, 2022 Vaccination offers the best way to prevent invasive meningococcal disease (IMD). As demonstrated in countries with national immunization programs (NIPs) against IMD, meningococcal conjugate vaccines have contributed to significant declines in incidence ...
Gary S. Marshall +3 more
doaj +1 more source
The Hajj 2019 Vaccine Requirements and Possible New Challenges [PDF]
, 2019 Each year millions of pilgrims perform the annual Hajj from more than 180 countries around the world. This is one of the largest mass gathering events and may result in the occurrence and spread of infectious diseases.
Al-Tawfiq, Jaffar A., Memish, Ziad A.
core +1 more source